BiomX Inc.

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity (capital deficiency)

Redeemable Convertible Preferred Shares · Common stock · Additional · Total Stockholder’ Equity
	Shares	Amount	Shares (****)	Amount	paid in Capital	Accumulated Deficit	(capital deficiency)
Balance as of January 1, 2024	-	-	314,943	3	166,048	(162,970)	3,081
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (**)	40,470	12,561	48,237	1	3,227	-	15,789
Exercise of Pre-Funded Warrants into shares of Common Stock	-	-	76,770	1	5	-	6
Issuance of Common Stock under an Open Market Offering Agreement, net of issuance costs (**)	-	-	396	*	19	-	19
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (**)	216,417	19,859	-	-	541	-	20,400
Redeemable Convertible Preferred Shares conversion into shares of Common Stock	(109,152)	(13,775)	574,484	1	13,774	-	-
Issuance of Common Stock upon restricted stock units (“RSUs”) vesting	-	-	8,180	*	-	-	*
Stock-based compensation expenses	-	-	-	-	2,580	-	2,580
Net loss	-	-	-	-	-	(17,727)	(17,727)
Balance as of December 31, 2024	147,735	18,645	1,023,010	6	186,194	(180,697)	24,148
Issuance of Common Stock, Registered Pre-Funded Warrants and Private Pre-Funded Warrants under the February 2025 SPA, net of issuance costs (**)	-	-	148,857	*	878	-	878
Issuance of Common Stock under the Inducement Letter Agreements (**)	-	-	208,479	1	6,472	-	6,473
Exercise of Private Pre-Funded Warrants and Common Warrants (**)	-	-	75,223	*	2	-	2
Exercise of options to Common Stock (***)	-	-	718	*	*	-	*
Vested restricted stock units (***)	-	-	14,469	*	-	-	*
Issuance of Common Stock under the At the Market Sales Agreement, net of issuance costs (**)	-	-	121,773	*	1,305	-	1,305
Conversion of Redeemable Convertible Preferred Shares into Common Stock (**)	(223)	(28)	1,174	*	28	-	-
Stock-based compensation expenses	-	-	-	-	2,091	-	2,091
Net loss	-	-	-	-	-	(36,199)	(36,199)
Balance as of December 31, 2025	147,512	18,617	1,593,703	7	196,970	(216,896)	(1,302)

(*)	Less than $1.
(**)	See note 12A.
(***)	See note 12B.
(****)	All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 12A.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.